Osteoprotegerin (OPG)/RANK-L System in Juvenile Idiopathic Arthritis: Is There a Potential Modulating Role for OPG/RANK-L in Bone Injury?

Journal of Rheumatology

Volumn 31, Issue 5, 2004, Pages 986-991

  Masi, Laura ^a   Simonini, Gabriele ^a   Piscitelli, Elisabetta ^a   Del Monte, Francesca ^a   Giani, Teresa ^a   Cimaz, Rolando ^b   Vierucci, Silvia ^a   Brandi, Maria Luisa ^d   Falcini, Fernanda ^a,c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b PARKINSON INSTITUTE   (Italy)

^c Rheumatology Unit   (Italy)

^d NONE

Author keywords

Bone and cartilage damage; Juvenile idiopathic arthritis; Osteoprotegerin; Rank ligand

Indexed keywords

C REACTIVE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

AGE; ALLELE; ARTHRITIS; ARTICLE; BONE EROSION; BONE INJURY; BONE MASS; BONE RADIOGRAPHY; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENDER; GENOTYPE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS;

ARTHRITIS, JUVENILE RHEUMATOID; BLOOD SEDIMENTATION; BONE DENSITY; BONE RESORPTION; CARRIER PROTEINS; CHILD; CHILD, PRESCHOOL; DNA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLYCOPROTEINS; HUMANS; JOINTS; MALE; MEMBRANE GLYCOPROTEINS; OSTEOPROTEGERIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SYNOVIAL FLUID; TIME FACTORS;

EID: 2342598382     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Cassidy JT. Juvenile rheumatoid arthritis. In: Cassidy JT, Petty RE, editors. Textbook of pediatric rheumatology. Fourth ed. New York: Churchill Livingston; 2001:113-219.
2. Rabinovich CE. Bone mineral status in juvenile rheumatoid arthritis. J Rheumatol 2000;27:34-7.
3. Kotaniemi A. Growth retardation and bone loss as determinants of axial osteopenia in juvenile chronic arthritis. Scand J Rheumatol 1997;26:14-8.
4. Pepmuller PH, Cassidy JT, Allen SH, Hillmann L. Bone mineralization and bone mineral metabolism in children with juvenile rheumatoid arthritis. Arthritis Rheum 1996;39:746-57.
5. Jimi E, Nakamura J, Amano H, et al. OC function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology 1996;137:2187-90.
6. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998;152:943-51.
7. Goldring SR, Gravallese EM. Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 2000;12:195-9.
8. Hofbauer LC. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Eur J Endocrinol 1999;141:195-210.
9. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie Mt, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-57.
10. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-κB and osteoprotegerin in bone cell biology. J Mol Med 2001;79:243-53.
11. Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFkB ligand and tumor necrosis factor-alfa in bone destruction in rheumatoid arthritis. Arthritis Rheum 2002;30:340-6.
12. Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporosis Int 2000;11:905-13.
13. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12.
14. Gravallese EM, Galson DL, Goldring SR, Auron PE. The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. Arthritis Res 2001;3:6-12.
15. Kostenuik PJ, Shalhoub V. Osteoprotegerin: a physiological inhibitor of bone resorption. Curr Pharm Res 2001;7:613-35.
16. Bolon B, Shalhoub V, Kostenuik PJ, et al. Osteoprotegerin: an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. Arthritis Rheum 2002;46:3121-35.
17. Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Eberl S. Genetic determinants of bone mass in adults: a twin study. J Clin Invest 1987;80:706-10.
18. Hofbauer LC, Heufelder AE. The role of osteoprotegerin and receptor activator of nuclear factor κB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 2001;44:253-9.
19. Itonaga I, Fujikawa Y, Sabokbar A, Murry DW, Athanasou NA. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. J Pathol 2000;192:97-104.
20. Petty RE, Southwood TR, Baum J, et al. Durban 1997. J Rheumatol 1998;25:1991-4.
21. Wuyts W, Van Wesenbeeck L, Morales-Piga A, et al. Evaluation of the role of RANK and OPG genes in Paget's disease of bone. Bone 2001;28:104-7.
22. Kong YY, Yoshida H, Sarosi, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
23. Kong YY, Feige U, Sarosi I, Bolon B, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9.
24. Hofbauer LC, Schopper M. Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet 2001;358:257-9.
25. Takayanagi H, Iizuka H, Juji T, et al. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis form synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000;43:259-69.
26. Campagnuolo G, Bolon B, Feige U. Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum 2002;46:1926-36.
27. Browner WS, Lui Li-Y, Cummings SR. Association of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrin Metab 2001;86:631-7.
28. Yano K, Tsuda E, Washida N, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999;14:518-27.
29. Arrighi H, Khosla S, Melton LJ, Riggs B, Bekker P, Dunstan CR. The relationship between circulating osteoprotegerin and estrogen in postmenopausal women. J Bone Miner Res 2000;15 Suppl 1:M344.
30. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
31. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-8.
32. Arko B, Prezelj J, Komel R, Kocijancic A, Hudler P, Marc J. Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis. J Clin Endocrinol Metab 2002;87:4080-4.
33. Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF. Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. J Bone Miner Res 2002;17:1245-55.